Alfred Wang
About Alfred Wang
Alfred Wang serves as the Vice President of Commercial Strategy and New Product Planning at Structure Therapeutics, having previously held senior roles at Chinook Therapeutics and Exelixis. He holds a PhD in Molecular Pharmacology from Stanford University and a B.S. in Biology from Caltech.
Current Role at Structure Therapeutics
Alfred Wang serves as the Vice President of Commercial Strategy & New Product Planning at Structure Therapeutics. He has been in this role since 2024, contributing to the company's strategic initiatives in South San Francisco, California. His responsibilities include overseeing commercial strategies and planning for new product launches in a hybrid work environment.
Previous Experience at Chinook Therapeutics
Prior to his current position, Wang worked at Chinook Therapeutics, Inc. as the Executive Director of Marketing & New Product Planning from 2022 to 2024. During his tenure in Oakland, California, he focused on marketing strategies and the planning of new product introductions, enhancing the company's market presence.
Experience at Exelixis
Alfred Wang held multiple roles at Exelixis, where he was Executive Director of Commercial Strategy & Planning from 2018 to 2022 and Senior Director of Market Planning from 2016 to 2018. His work in Alameda and South San Francisco, California, involved developing and executing commercial strategies that supported the company's product portfolio.
Educational Background
Wang earned a Bachelor of Science degree in Biology from the California Institute of Technology (Caltech) from 1995 to 1999. He furthered his education at Stanford University School of Medicine, where he obtained a PhD in Molecular Pharmacology from 2000 to 2006. His academic background provides a strong foundation for his career in the pharmaceutical and biotechnology industries.
Early Career and Internships
Alfred Wang began his career with internships at Roche Bioscience and Genentech in 1998 and 1999, respectively. He later worked at IMS Consulting Group and Strategic Decisions Group, where he gained experience in strategy and portfolio analysis. This early experience contributed to his expertise in commercial strategy and planning.